A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

Inclusion Criteria: * Adult patients, \>/= 50 years of age * Patients with age-related macular degeneration (AMD) * Best corrected visual acuity (BCVA) of 20/40 to 20/400 (Snellen equivalent, on ETDRA charts) inclusive * Evidence of leakage due to choroidal neovascularization (CNV) Exclusion Criteria: * Choroidal neovascularization (CNV) in either eye due to causes other than age related macular degeneration, such as ocular histoplasmosis, trauma, or pathologic myopia * Known hypersensitivity to ranibizumab, fluorescein, indocyanin green (ICG) or any of the ingredients of the formulation used, or any of the medications used * Any other restriction according to the use of ranibizumab * Active intraocular inflammation (grade trace or above) in the study eye * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye